Genetic dominance of transforming growth factor-1 polymorphisms in chronic liver disease

Xuanyan Cai,Huiyan Zha,Zhaoxu Yang,Yiwen Du,Xiaoyang Dai,Bo Yang,Jiajia Wang,Qiaojun He,Qinjie Weng
DOI: https://doi.org/10.3389/fimmu.2022.1058532
IF: 7.3
2022-01-01
Frontiers in Immunology
Abstract:Chronic liver disease (CLD) is an extremely common clinical condition accompanied by sustained inflammatory response leading to tissue damage. Transforming growth factor-beta 1 (TGF-beta 1) is known as a master immune regulator in CLDs, but the association between TGF-beta 1 polymorphisms and CLD risk is controversial and inconclusive, and the genetic dominance of CLDs remains unknown. In this study, the relationship between TGF-beta 1 polymorphisms and CLD susceptibility is systematically analyzed based on 35 eligible studies. Individuals with the TGF-beta 1-509 allele (TT or CT) or codon 10 allele (Pro/Pro) show an increased risk of CLDs. Subgroup analyses indicate TGF-beta 1-509C/T has a significant correlation with cirrhosis and chronic hepatitis C, codon 10 is associated with chronic hepatitis B occurrence, and codon 25 exhibits a relationship with autoimmune hepatitis risk. Missense mutations in G29E, A105S, D191N, and F321L of TGF-beta 1 are the genetic factors of HCC susceptibility. Furthermore, the TGF-beta 1 gene expression is significantly elevated in CLD patients, and the TGF-beta 1 codon 263 is located close to the region where the TGF-beta 1 dimerization interacts, indicating the TGF-beta 1 codon 263 variant may affect the secretion of TGF-beta 1 by altering its dimerization. Together, our findings provide new insights into the immune regulator gene TGF-beta 1 polymorphisms as susceptibility factors for CLD occurrence and regulators for TGF-beta 1 expression, which have implications for the regulation of immune factors during CLD development.
What problem does this paper attempt to address?